Junshi Biosciences Narrows 2025 Loss as Revenue Climbs Nearly 30%

An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.

Shanghai Junshi Biosciences Co., Ltd., a China-based biopharmaceutical developer of innovative antibody drugs and other advanced therapies, operates in the competitive global healthcare market with a focus on major disease areas. The company is listed in both Shanghai and Hong Kong, and reports its financials under PRC GAAP and IFRS, reflecting its cross-border capital markets presence.

For 2025, the company reported a preliminary 28.23% increase in total operating income to RMB 2.50 billion, while significantly narrowing its net loss attributable to shareholders to approximately RMB 874 million, aided by improved operating performance and reduced losses excluding share-based payment impacts. Total assets rose nearly 15% and return on net assets improved, although the business remains loss-making, and management has cautioned investors that the figures are unaudited and subject to change in the forthcoming annual report.

The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.

More about Shanghai Junshi Biosciences Co., Ltd. Class H

Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative drugs. The company concentrates on antibody therapeutics and other advanced treatments, targeting major disease areas and competing in both domestic and international healthcare markets.

Average Trading Volume: 3,054,154

Technical Sentiment Signal: Sell

Current Market Cap: HK$35.28B

See more data about 1877 stock on TipRanks’ Stock Analysis page.